A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.

PubWeight™: 1.10‹?› | Rank: Top 10%

🔗 View Article (PMID 21330911)

Published in AIDS on March 27, 2011


Jonathan B Angel1, Jean-Pierre Routy, Cecile Tremblay, Dieter Ayers, Ryan Woods, Joel Singer, Nicole Bernard, Colin Kovacs, Fiona Smaill, Sanjay Gurunathan, Rafick-Pierre Sekaly

Author Affiliations

1: Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada. jangel@ohri.ca

Associated clinical trials:

Combination Vaccination Before HIV Treatment Interruption | NCT00212888

Articles citing this

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

HIV-1 DNA predicts disease progression and post-treatment virological control. Elife (2014) 2.07

Immunologic strategies for HIV-1 remission and eradication. Science (2014) 1.70

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20

The evolution of poxvirus vaccines. Viruses (2015) 1.02

Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology (2012) 0.90

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. J Virol (2015) 0.86

Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.81

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr (2016) 0.80

Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China. PLoS One (2014) 0.80

Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc (2015) 0.78

The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy). J Acquir Immune Defic Syndr (2015) 0.75

Articles by these authors

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15

Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature (2003) 12.10

Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med (2008) 11.00

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45

High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70

Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 6.17

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25

Less-tight versus tight control of hypertension in pregnancy. N Engl J Med (2015) 5.03

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67

HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med (2003) 4.53

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26

Characterization of airway plugging in fatal asthma. Am J Med (2003) 3.23

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med (2012) 3.05

HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity (2004) 2.86

Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80

Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77

Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med (2009) 2.77

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68

Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40

Alcohol consumption as a trigger of recurrent gout attacks. Am J Med (2006) 2.39

Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol (2003) 2.36

Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34

Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol (2007) 2.32

Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med (2002) 2.31

Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med (2014) 2.27

Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med (2006) 2.27

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion (2007) 2.19

Safety and efficiency of emergency department assessment of chest discomfort. CMAJ (2004) 2.09

Socioemotional effects of fathers' incarceration on low-income, urban, school-aged children. Pediatrics (2007) 2.07

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A (2010) 2.07

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother (2005) 2.07

Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol (2007) 2.03

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01

Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94

Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 1.92

Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89

Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum (2004) 1.87

Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med (2008) 1.85

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83

Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol (2009) 1.79

Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol (2006) 1.79

Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain (2003) 1.77

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73

Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72

Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.69

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65

CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses (2007) 1.64

Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61

Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol (2010) 1.61

HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol (2010) 1.60

Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60

Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol (2004) 1.59

A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 1.58

Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J Infect Dis (2005) 1.58

One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ (2007) 1.55

Clinical decision rules to improve the detection of adverse drug events in emergency department patients. Acad Emerg Med (2012) 1.52

Agreement in electrocardiogram interpretation in patients with septic shock. Crit Care Med (2011) 1.52

Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol (2009) 1.52

Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol (2011) 1.51

High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis (2005) 1.49

A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (2008) 1.47

Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS (2007) 1.47

Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Crit Care (2013) 1.46

Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46

Reliability of the knee examination in osteoarthritis: effect of standardization. Arthritis Rheum (2004) 1.46

Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis (2002) 1.44

Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44

Factors other than the Duke criteria associated with infective endocarditis among injection drug users. Clin Invest Med (2002) 1.44